Actively Recruiting
Exploring the Effectiveness and Safety of Zeprumetostat in Treating Relapsed or Refractory Large Granular Lymphocyte Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-11-04
10
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring the effects and safety of zeprumetostat in patients with relapsed or refractory large granular T-cell leukemia. This single-arm, early-phase clinical trial plans to enroll 10 patients who have this rare blood cancer and have not responded well to previous treatments. The purpose is to understand how well zeprumetostat works and how safe it is for these patients. Participants will first go through up to a 4-week screening period before starting treatment. They will then receive oral zeprumetostat at a dose of 350 mg twice daily for 28 days, which counts as one treatment cycle. The treatment phase lasts for two cycles 8 weeks total. If side effects occur, the treatment may be paused and restarted following specific guidelines. During the study, participants will be closely monitored for how many achieve hematological remission after two treatment cycles. Researchers will also track side effects, time to partial or complete remission, quality of life changes, and how long benefits last before disease recurrence. The study includes regular assessments and aims to understand both the treatments impact and safety over at least eight weeks, with some follow-up planned for up to two years.
CONDITIONS
Brief Title
A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here